Pola Orbis Holdings Inc.
www.po-holdings.co.jp
Latest From Pola Orbis Holdings Inc.
Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
In Brief: NPD On Cosmetic Shoppers; African Beauty Market; Avon’s FY 2014
The NPD Group reports a 4% decline in U.S. beauty shoppers in 2014; Avon releases its fiscal 2014 results, while Energizer announces its personal-care spinoff will be called Edgewell Personal Care. More news in brief.
Ranbaxy markets Summit's luliconazole in India
Ranbaxy Laboratories has launched the antifungal luliconazole (marketed as Lulifin) in India. The product is licensed from Japan's Summit Pharmaceuticals International Corporation (SPI).
Pola deal to boost GSK's Japanese dermal business
Pola Pharma is to begin co-promoting four GlaxoSmithKline topical products in Japan from July 1st, in a tie-up aimed at strengthening the UK group's presence in this sector.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice